About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Thursday, January 25th, 2018

The QualityStocks
Daily Stock List


Identillect Technologies Corp. (IDTLF)

OTC Markets, InvestorsHub, Investors Hangout, Stockhouse, Investopedia, and Stock Orange reported on Identillect Technologies Corp. (IDTLF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Identillect Technologies Corp. is a foremost provider of SaaS (Software as a Service) email security. The Company’s Delivery Trust™ email security technology platform enables individuals and businesses of all sizes a cost-effective way to create a more secure digital environment and protect against cyber security risks. Identillect Technologies has its corporate office in Irvine, California.  
Delivery Trust™ is the industry’s simplest plug and play security solution. It is an award -winning, multi-platform plug-in, which gives users total control of their emails, for one low price. Delivery Trust™ is available for iPhone®, iPad®, Android, Windows, and Mac PC's and Laptops and the web's most popular email platforms. 

Delivery Trust™  has a wide range of features. These include state-of-the-art encryption technology, restricting email forwarding and printing, receipt confirmation, limiting time available to view, and also retracting sent emails.
Identillect Technologies has a service collaboration with the National Association of Professional Agents (NAPA), providing NAPA members access to the Company's set of compliance tools. This includes the Identillect Delivery Trust™ email encryption service. NAPA specializes in building custom company-sponsored E&O and benefit programs tailored to meet the unique requirements of a sponsoring company’s distribution force. 
Last month, Identillect Technologies announced a joint project with QubeChain LLC to provide Multi-Factor Authentication (MFA) with its Self-Sovereign ID (SSI) platform, an enhanced level of security for organizations at higher risk or with advanced security demands. QubeChain is built to promote transformation by taking advantage of creative innovation and deep industry expertise to produce Applied Uses of Blockchain Technology across all industries.

Last week, Identillect Technologies announced excellent growth for 2017. Subscriber growth saw increases of 56 percent over prior subscriber base numbers.

Mr. Todd Sexton, Identillect Technologies’ Chief Executive Officer, stated, "Identillect is excited about the growth we have seen in 2017, advancements in the technology of Delivery Trust will continue to motivate new industries utilizing our products to prevent security breaches within their businesses. The growth in cloud service offerings along with the need for blockchain technologies makes Delivery Trust the ideal product for organizations spanning almost every industry to advance their security protocols.”

Yesterday, Identillect Technologies announced the launch of a multi-faceted digital campaign to the legal community using the legal marketing specialists at Market My Market. Identillect chose the legal marketing specialists at Market My Market to boost multi-avenue digital campaigns to legal professionals throughout the country.

Identillect’s campaigns with Market My Market to the U.S. population of greater than 1.3 million lawyers and many state bar associations’ aims to further solidify the Company’s Delivery Trust® as the email security solution of choice for professionals in the legal community.

Identillect Technologies Corp. (IDTLF), closed Thursday's trading session at $0.195, down 9.18%, on 77,786 volume with 24 trades. The average volume for the last 60 days is 210,496 and the stock's 52-week low/high is $0.0464/$0.4763.

InterCloud Systems, Inc. (ICLD)

INO Market Report, BUYINS.NET, GreatStockPix, Street Insider, Microcapmillionaires, PennyPro, Promotion Stock Secrets, Marketbeat, Broad Street, StocksImpossible, OTCBB Journal, Stock Onion, Stock Tips Network, Buzz Stocks, Greenbackers, Jason Bond, RedChip, Wealthpire Inc., PennyStockProphet, Penny Pick Finders, Planet Penny Stocks, Hit and Run Candle Sticks, and Investing Futures reported previously on InterCloud Systems, Inc. (ICLD), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

InterCloud Systems, Inc. is a leading provider of cloud networking orchestration and automation solutions and services. The Company provides the modern-day Information Technology (IT) and network solutions to the enterprise markets via cloud computing and professional services. InterCloud provides cloud services (SaaS, PaaS, and IaaS), professional consulting, data solutions, and maintenance services. 

Established in 2006, the Company’s mission is to enable carriers to speed up the installment of Virtualized Network and IT Services. InterCloud Systems is based in Shrewsbury, New Jersey. The Company lists on the OTC Markets Group’s OTCQB.

InterCloud is a top provider of cloud networking orchestration and automation for Software Defined Networking (SDN) and Network Function Virtualization (NFV) cloud environments. The Company is a provider to the telecommunications service provider (carrier) and corporate enterprise markets.

The Company’s cloud solutions provide enterprise and service-provider customers the opportunity to adopt an operational expense model through outsourcing cloud deployment and management to InterCloud Systems.

InterCloud’s products and solutions include NFVGrid – NFVO Management & Analytics Platform. This is a full scale next generation networking platform for virtualized network functions. NFVGrid is proprietary IP. However, NFVGrid completely embraces Open Source.

InterCloud Systems’ solutions include Disaster Recovery. The Company’s cloud backup permits one to backup their vital business data to a remote and secure location for quick disaster recovery.

Regarding its Professional Services, InterCloud Systems has a 24×7 practice for numerous technologies. These includeUnix / Linux System Administration; Microsoft System Administration; VMware Administration; and ​ Open Stack / Cloud Stack. These additionally include Juniper Design, Operate & Support; ​ Cisco Design, Operate & Support; as well as Citrix Design, Operate & Support.

Recently, InterCloud Systems announced that its Netlayer.io software platform became a technology partner with Computer Associates (CA). Netlayer.io was recently chosen by CA as a Technology Partner. The integrated solution was presented at the CA World convention, which took place in Las Vegas, Nevada in November 2017.

Netlayer.io integrates with CA’s network monitoring and analytical systems. The integrated Netlayer.io/CA solution provides end-to-end orchestration and monitoring functions for next-generation virtualized networking environments. This includes SDN, NFV, as well as SD-WAN.

CA monitoring and analytics by way of Netlayer.io's orchestration permits reactive and proactive actions founded on CA's analytics input.

InterCloud Systems, Inc. (ICLD), closed Thursday's trading session at $0.003, down 6.25%, on 13,589,687 volume with 83 trades. The average volume for the last 60 days is 25,146,571 and the stock's 52-week low/high is $0.0017/$0.394.

RenovaCare, Inc. (RCAR)

Insider Financial, Zacks, and MarketWatch reported on RenovaCare, Inc. (RCAR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

RenovaCare, Inc. is developing first-of-their-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. The Company’s first product under development targets the body’s largest organ, the skin. RenovaCare is the developer of the patented CellMist™ and SkinGun™ technologies. These are for isolating and spraying a patient’s own stem cells onto burns and wounds for fast self-healing.

RenovaCare is based in New York, New York and the Company lists on the OTCQB. It previously went by the name Janus Resources, Inc. It changed its name to RenovaCare, Inc. in January of 2014.

The Company’s flagship technology, the CellMist™ System, utilizes its patented SkinGun™ to spray a liquid suspension of a patient’s stem cells – the CellMist™ Solution – onto wounds. RenovaCare is developing its CellMist™ System as a promising new option for patients suffering from burns, chronic and acute wounds, as well as scars.

The CellMist™ System targets patients around the world who suffer burns, chronic and acute wounds, acne scarring, and skin defects and diseases such as vitiligo. RenovaCare’s approach to isolating a patient’s own stem cells for subsequent spray onto burns and wounds was validated by researchers in ‘Differentiation’, a leading peer-reviewed scientific publication. According to their findings, the methodology that has been adopted by RenovaCare successfully isolates those specific cell populations with the greatest regenerative capacity to support the growth of fully-functioning skin.

In investigative clinical use in the United States SkinGun™ treatments have shown the potential to naturally and quickly heal burns and other serious wounds. Based on preliminary case studies, CellMist™ System patients can be treated within 90 minutes of entering an emergency room. A patient’s stem cells are isolated, processed, and sprayed onto wound sites for rapid healing.

Skin stems cells sprayed with the Company’s patented SkinGun™ device maintain 97.3 percent cell viability. There is no impairment to cell growth or metabolic activity when evaluated in vitro. The SkinGun™ is now on display at the prestigious Science Museum in London (founded in 1857).

RenovaCare has a partnership to validate the science behind its innovative technology for treatments of wounds, burns, and other skin defects. The Company’s research partner is Berlin-Brandenburg Center for Regenerative Therapies (BCRT). This is a translational research center at Charité - Universitätsmedizin Berlin, one of the world’s largest university hospitals.

In 2017, RenovaCare had studies in prestigious journals. In addition, the Company miniaturized the SkinGun™ from the size of a microwave to a device that fits comfortably in one hand.

To date, as of January 9, 2018, 72 patients have been treated, with 45 in Pittsburgh, Pennsylvania, and 27 in Berlin, Germany. Nineteen of the Berlin patients were treated with an early prototype of RenovaCare’s SkinGun™.

The next significant milestone for the Company will be its initial Food and Drug Administration (FDA) filing. The FDA filing will advance RenovaCare’s pioneering technology towards market. Its initial FDA filing will be to demonstrate the safety and efficacy of its approach for treating wounds employing a patient’s own skin cells.

RenovaCare, Inc. (RCAR), closed Thursday's trading session at $5.42, up 4.23%, on 43,302 volume with 101 trades. The average volume for the last 60 days is 49,535 and the stock's 52-week low/high is $2.30/$6.35.

ImmuDyne, Inc. (IMMD)

PennyStocks24, Penny Pick Finders, SecretStockPromo, Buzz Stocks, Planet Penny Stocks, PennyStockProphet, and StockOnion reported previously on ImmuDyne, Inc. (IMMD), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

ImmuDyne, Inc. is a health, wellness, and skincare company commercializing a portfolio of proprietary topical and orally delivered products. These rely on the Company’s patented and pure Yeast Beta Glucan ingredients. ImmuDyne has developed proprietary topical and oral products and proprietary natural delivery technology with manifold new market opportunities. The Company is a leader in the development and online marketing of OTC (Over the Counter) health and wellness products addressing significant unmet needs.  

Immudyne PR is a majority-owned subsidiary of ImmuDyne, Inc. ImmuDyne has offices in Mt. Kisco, New York; Huntington Beach, California; San Juan, Puerto Rico; and Florence, Kentucky. ImmuDyne lists on the OTC Markets Group’s OTCQB.   

ImmuDyne says that it is well-established in the scientific community that beta-glucans are strong activators of the innate immune response. Recent studies indicate that yeast beta-1,3/1,6-D-glucans can also activate adaptive immune responses.

In addition, the Company manufactures and sells yeast beta-1,3/1,6 glucan for oral and topical uses. ImmuDyne’s strategy is to create new market spaces within the wellness industry via the launch of clinically researched, doctor recommended immune support products and services. Through a highly complex, proprietary process that uses best-in-class technology, the Company can extract highly purified beta-1,3/1,6-D-glucan from the cell walls of Saccaharomyces cerevisiae.

Nationally, ImmuDyne has launched its patented Shapiro MD product line. The Shapiro MD product line is the result of 15 years of research and development by dermatologists Dr. Steven Shapiro and Dr. Michael Borenstein. It is protected by two United States patents.

ImmuDyne PR is the digital marketing arm of ImmuDyne. ImmuDyne PR is currently centering on marketing products for thicker and fuller hair (Shapiro MD) and a skincare line containing Immudyne’s proprietary Yeast Beta Glucan ingredient (Inate MD). The InateMD product line contains an ultra-pure Yeast Beta Glucan compound proven to support the human immune system.

This past November, ImmuDyne announced that the Company made a strategic investment and now owns 1,000,000 common shares of Blockchain Industries, Inc. (OMGT).

Mr. Mark McLaughlin, ImmuDyne’s Chief Executive Officer, stated, “ImmuDyne believes that blockchain technologies have the ability to transform the online world. We think this specific strategic investment could be a fantastic windfall for all ImmuDyne shareholders, with very little proportionate risk. Additionally, our relationship with Blockchain Industries will give us a valuable partner and exposure to new companies and technologies that can support our core business of building and marketing innovative online proprietary brands.”

ImmuDyne, Inc. (IMMD), closed Thursday's trading session at $0.313, even for the day, on 12,564 volume with 10 trades. The average volume for the last 60 days is 69,081 and the stock's 52-week low/high is $0.21/$0.95.

NextSource Materials, Inc. (NSRCF)

InvestorIntel, MarketWatch, OTC Markets, Stockhouse, BusinessInsider, GuruFocus, Investing News, 4-Traders, and Zacks reported on NextSource Materials, Inc. (NSRCF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

NextSource Materials, Inc. is a mine development company listed on the OTC Markets Group’s OTCQB. It is developing its 100 percent-owned Molo Graphite Project in southern Madagascar. The Company previously went by the name Energizer Resources, Inc. It changed its corporate name to NextSource Materials Inc. in April of last year. NextSource Materials has its head office in Toronto, Ontario.

The Company’s Molo Graphite Project is a Feasibility-Stage project. It ranks as one of the largest-known and highest quality flake graphite deposits globally and the only project with SuperFlake® graphite.

The Molo Graphite Project is 160 km by road southeast of Madagascar’s administrative capital (and port city) of Toliara, and 220 km from the Port of Ehoala at Fort Dauphin. Mining is viewed very positively by the Madagascar government and a key economic driver for the nation.

The Project hosts a National Instrument 43-101 (NI 43-101) compliant total combined graphite resource of 141.28 million tonnes (Mt) at 6.13 percent total graphitic carbon (C), with a contained ore reserve of 22.44 Mt at 7.02 percent C. The Molo Graphite Project is verified to have one of the lowest operating costs in the industry, based on a full-cost CIF-basis.

Phase 1 at Molo will comprise a processing plant with a feed rate of 240,000 tonnes per annum and a production rate of about 15,000 tonnes of finished flake graphite concentrate at purities between 97 percent C to 98 percent C per annum. Phase 2 will be the expansion of SuperFlake™ production to 50,000 tonnes per annum, as foreseen in NextSource Materials’ 2015 Feasibility Study.

Currently, NextSource Materials is concentrating on advancing the Molo Project to production. Commissioning and production are expected this year. Traditional demand for graphite today is mostly tied to the steel industry, which accounts for roughly 52 percent of total graphite demand.

Moreover, NextSource Materials holds a 100 percent interest in the Green Giant property. Green Giant encompasses an area of 225 square kilometers situated in the Southern Madagascar Region, Madagascar.

This month, NextSource Materials announced that it successfully registered SuperFlake® as a trademark in Japan. The registration of the SuperFlake® trademark means that the Company now has the exclusive right to use this trademark on all natural graphite sold in Japan, which it produces from its Molo Graphite Project.

NextSource Materials now has registered trademark status of SuperFlake® graphite in Japan and the entire European Union (EU). In addition, NextSource applied for and is expecting to be awarded the exclusive right to use SuperFlake® in the U.S., Canada, and South Korea.

NextSource Materials, Inc. (NSRCF), closed Thursday's trading session at $0.147, up 25.11%, on 2,616,290 volume with 93 trades. The average volume for the last 60 days is 160,161 and the stock's 52-week low/high is $0.0405/$0.142.

Nexeon MedSystems, Inc. (NXNN)

NetworkNewsWire, Stockhouse, Stockopedia, Zacks, Street Insider, Barchart, and InvestorsHub reported on Nexeon MedSystems, Inc. (NXNN), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Nexeon MedSystems, Inc. concentrates on providing innovative neurostimulation products. Its focus is on providing neurostimulation products that improve the quality-of-life of patients suffering from debilitating neurological diseases. A global bioelectronics medical device company, Nexeon MedSystems has offices in Dallas, Texas and Liege, Belgium (Nexeon MedSystems Belgium SPRL).

Nexeon has developed and commercialized a neurostimulation system. This system can be used to treat a variety of neurological diseases.

Neurostimulation systems are utilized to restore neuronal function. The Company’s SYNAPSE™ device is the platform used in a process called Deep Brain Stimulation (DBS).

This platform acts like a brain pacemaker sending electrical pulses to specifically targeted areas in the brain. SYNAPSE™ reduces shortcomings in contemporary DBS therapy. It enables the detection, measurement, as well as collection of brain signals, while simultaneously providing targeted DBS therapy. Furthermore, it provides directional stimulation that limits side effects.

In addition, multiple stimulation frequencies allow increased therapy range. Additionally, rechargeable means a greater range of available therapies and rechargeable enables one surgery in comparison to many. The plan is for the DBS commercial launch in Q2 of 2018.

Nexeon MedSystems earlier exercised its option to acquire Nexeon Medsystems Belgium, SPRL (NMB). NMB has been operating since 2013 developing neurostimulation products.

NMB recently acquired Medi-Line. This is a Belgian medical device manufacturer. Medi-Line currently serves 34 medical device customers in 16 nations. It has multi-year contracts with Fortune 500 companies.

Nexeon MedSystems announced in October of 2017 its completion of an initial series of clinical studies evaluating the use of transcutaneous auricular vagus nerve stimulation (aVNS) for the relief of paroxysmal atrial fibrillation. The Company was previously awarded a €3.4M research grant regarding this study from the Walloon Region government of Belgium in coordination with the region's health competitiveness cluster BioWin.

For Q3 2017, Nexeon MedSystems closed the acquisition of Nexeon MedSystems Belgium, SPRL (previously Rosellini Scientific Benelux) and its wholly-owned subsidiaries Med-Line S.A. and its holding company INGEST, SPRL. The Company also completed regulatory pathway review with the European regulatory body DEKRA and the Food and Drug Administration (FDA) for its flagship deep brain stimulation product.

Nexeon MedSystems, Inc. (NXNN), closed Thursday's trading session at $0.80, up 32.93%, on 30,506 volume with 10 trades. The average volume for the last 60 days is 3,351 and the stock's 52-week low/high is $0.40/$2.50.

Mojo Organics, Inc. (MOJO)

InvestorsHub and Business Insider reported on Mojo Organics, Inc. (MOJO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Mojo Organics, Inc. engages in the product development, production, marketing, and distribution of beverages. The Company’s beverages are Non GMO Project Verified. Its products include coconut water, sparkling coconut water, as well as tropical juice. Incorporated in 2007, Mojo Organics’ shares trade on the OTC Markets Group’s OTCQB. The Company is headquartered in Jersey City, New Jersey.

Non GMO Project Verified is the highest certification. MOJO beverages have zero added sugar, no preservatives and low sodium. In addition, MOJO is vegan and gluten free.

MOJO coconut water comes in four flavors. These are regular coconut water, pineapple juice, passion fruit juice, and mango juice. The Company’s sparkling coconut water comes in the same four flavors.

Mojo Organics’ tropical juice comes in three flavors. These are mangosteen juice, dragon fruit juice, and pomel juice.

This past November, Mojo Organics reported its Q3 2017 operating results. Revenue for the three-month period was $439,560. This represents a drop of $71,098 from the same period the year prior. The drop in Revenue was because of the Company transitioning to the MOJO brand from private label business offset by growth in the MOJO branded business.

Gross Profit was $187,251.This represents a decrease of $24,801 from the same period the year prior.

The Net Loss for the period decreased to $18,778 from $97,937 for the same period last year. The improvement of $81,567 or 539 percent was chiefly because of a reduction in expenses of a non-recurring nature.

Mr. Glenn Simpson, Mojo Organics’ Chairman and Chief Executive Officer, said, "We are pleased to report that we ended our 2017 third quarter within our expectations. We continued to focus on increasing our points of sale and methods of distribution primarily in the northeast region and southeast region. We made significant progress in distribution and store count during the three-month period. In addition, we have now started selling to Kroger the largest USA grocer.”

Mojo Organics, Inc. (MOJO), closed Thursday's trading session at $0.75, up 316.67%, on 2,535,523 volume with 2,367 trades. The average volume for the last 60 days is 3,197 and the stock's 52-week low/high is $0.12/$0.355.


The QualityStocks
Company Corner


Medical Innovation Holdings, Inc. (MIHI)

The QualityStocks Daily Newsletter would like to spotlight Medical Innovation Holdings, Inc. (MIHI). Today, Medical Innovation Holdings, Inc. closed trading at $0.6689, up 37.92%, on 689,304 volume with 329 trades. The stock’s average daily volume over the past 60 days is 71,778, and its 52-week low/high is $0.1265/$3.99.

The parabolic rise in bitcoin and other cryptocurrencies has spawned a frenetic mania seldom seen in the markets. While debate of bitcoin’s legitimacy as a long-standing form of currency continues, general consensus asserts that the underlying blockchain technology has applications that extend far beyond its connections to cryptocurrency. As such, innovative companies around the globe are beginning to employ blockchain technology to streamline business and secure transactions. Telemedicine pioneer Medical Innovation Holdings, Inc. (MIHI) is establishing a new paradigm in secure and efficient handling of patient medical and financial data.

Medical Innovation Holdings, Inc. (MIHI), a Colorado-based publicly traded company, owns and operates strategically aligned healthcare service and product companies focused on the delivery of patient care, management services for physician offices, lab services, and pharma; and non-pharma medicines and alternatives to patients and consumers. Healthcare services are delivered and managed through the company's MSO, 3Point Care. 3Point Care uses virtual telemedicine with a unique customized software and hardware platform as a way of bringing quality medical care to rural and medically underserved areas (MUAs) of the country.

3Point Care provides personalized high-tech, high-touch telemedicine encounters that link virtual health specialty doctors with traditional primary physicians and their patients. This approach helps reduce the cost of care while enhancing the quality of care. The company's telemedicine approach is vastly different from other providers who rely on a monthly subscription to opt in the network and then require an encounter fee by the patient each and every time an on-demand physician is utilized. This approach breaks the continuum of care, relies on symptom-based diagnosis, does not accept insurance, and there is no certainty you are dealing with a licensed practitioner. In summation they are not a medical practice but a contract service to deliver virtual care. Because 3Point Care deploys doctors through an actual medical practice, there is no subscription fee. The company works with anyone and everyone that has insurance including Medicare and Medicaid. It works hand and hand with the patient's primary care physician so the continuum of care is always maintained. Part of the integrated software application enables the processing of insurance claims whereby doctors are paid for their services. This allows deductibles to be captured, allowing the patients to take advantage of medical tax deductions.

TeleLifeMd, a multi-disciplinary specialty healthcare practice with strong experience in telemedicine, is the primary deliverer of patient medical care. 3Point care has a unique and exclusive relationship with TeleLifeMD, acting as its management services organization by providing all levels of service that include scheduling, providing telemedicine hardware and software products and support, processing claims, paying all invoices and payroll incurred by TeleLifeMD, as well as any other service required to operate the practice.

BKare Diagnostics, another wholly owned subsidiary of MIHI, is tasked with delivering medical and health-related services such as laboratory testing, diagnostics, and alternative medicines primarily proven nutraceuticals. Its goal is to eventually infuse these products with 100% CBD/Hemp oil and THC-based oils to create new product categories as the law catches up with the cannabis marketplace. The opportunity to offer workable solutions that solve real health problems outside typical big pharma is very exciting for the company. It sees significant revenue opportunities in this space.

MIHI firmly believes the best way to provide access to high-quality medical care is through support and delivery of evidence-based virtual medicine, commonly known as telemedicine. With 80 million people living in rural, medically underserved areas of the nation, the company is poised to fill a glaring void in the healthcare industry by applying cutting-edge technology and time-tested business practices to deliver real-time care. Among the 16 areas of medical specialties available are cardiology, infertility, gastroenterology, pediatrics and obstetrics.

The company serves a number of constituents and stakeholders interested in reducing the cost of health care while simultaneously increasing the quality of care, improving access to health services for millions of people, and bringing value to company shareholders. Its unique platform incorporates every aspect of a telemedicine visit into a single, comprehensive package. Disclaimer

Medical Innovation Holdings, Inc. Company Blog

Medical Innovation Holdings, Inc. News:

The Underlying Value of Cryptocurrencies

MIHI Initiates Development of Blockchain Platform for Health Care Records and Payments Systems

MIHI Launches a New Health Care Sharing Organization (HCSO) Designed for 58 Million US-based Hispanics Requiring Coverage

Cache Elite Inc. (ILUS)

The QualityStocks Daily Newsletter would like to spotlight Cache Elite Inc. (ILUS). Today, Cache Elite Inc. closed trading at $0.01, off by 8.26%, on 2,837,600 volume with 34 trades. The stock’s average daily volume over the past 60 days is 873,973 and its 52-week low/high is $0.0021/$0.06.

In the United States, Cache Elite Inc. (ILUS) has deployed its travel agent host program through TripWitzConnection.com. “TripWitz will now make its proprietary software and supplier contracts available to the Independent Travel Agent working from home,” said CEO Derrick McWilliams. He went on to add, “These experienced agents will also be able to expand their business by the ability to accept Bitcoin as a new payment method for vacations. It also bodes well for planned projects that will deliver good quality content in a decentralized and compelling manner." 

Cache Elite Inc. (ILUS) is a forward-thinking technology and service provider. The company provides homeowners with the latest in 3D designs, decorative hardware (http://www.eliteknobs.com), and travel and vacation services. Its foray into travel-related services can be found at the TripWitz website (http://www.tripwitz.com) where its proprietary back-end software, called Internet Travel Management Software, helps TripWitz provide its customers with a distinctive, cost-effective and perfect travel experience that sets it apart from other online travel agencies such as Expedia and Travelocity.

TripWitz provides real-time, dynamically packaged vacation quotes that include airfare, hotels, villas, ground transportation and activities. Every client searching for a smarter way to travel will find TripWitz is able to cut out the stress and frustrations found with other online travel agents. The company provides its intuitive travel services to clients searching vacations possibilities at more than 20,000 destinations around the globe.

TripWitz contracts with over 500,000 hotels and connects with the world's airlines through Google's ITA Gateway software that allows for advanced availability solutions to satisfy millions of queries per second at the lowest possible fares. Seasonal rate fluctuations for many travel services, including ground transportation options, are included in the company's software, giving clients the best possible rates. TripWitz prides itself on giving users a friendly vacation experience that includes access to an experienced vacation destination specialist. Customers are never left to fend for themselves at any point of their vacation experience. TripWitz is also accepting Bitcoins, the international cryptocurrency, as payment for not only flights but vacations as well.

A new report published by Allied Market Research projects the global online travel market will reach an estimated $1,091 billion by 2022, with the Asia-Pacific region expected to witness the highest growth during the forecast period. Travelers are looking for sound help in making travel decisions that fit within their budgets. Younger travelers, those within the 21-31 year age bracket, are seen as a more mobile generation, using social media and smartphones for many of their travel planning and booking needs.

TripWitz is an accredited member of the CCRA (Travel Commerce Network), which connects the company to over 180,000 properties worldwide. TripWitz is also an ARC approval agency. ARC accredited agencies are the most select group of dedicated professionals in the U.S. travel industry and are recognized as having met stringent financial, personnel and security requirements.

The official press release announcing the recent launch of TripWitz can be found at the following link: Cache Elite Inc. (ILUS) Unveils New Venture Into the $341 Billion Travel Industry. Disclaimer

Cache Elite Inc. Blog

Cache Elite Inc. News:

Cache Elite (OTCPK: ILUS) Deploys TripWitz Connections, A Travel Agent Host Program

Cache Elite (ILUS), a Company Offering Intriguing Payment Options as Bitcoin Continues Rise and Acceptance

Cache Elite Inc. (ILUS) Engages NetworkNewsWire for Corporate Communications Solutions

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF). Today, PreveCeutical Medical Inc. closed trading at $0.435, up 24.29%, on 90,753 volume with 48 trades. The stock’s average daily volume over the past 60 days is 408, and its 52-week low/high is $0.01/$0.70.

The rapidly growing cannabis industry has spawned a range of diverse companies focusing on innovative technologies for cannabis cultivation, as well as the development of cannabis-based medical therapies for an array of diseases and ailments. The market has given rise to biotech companies with exciting advances in product formulation and delivery. At the cutting-edge of innovation, PreveCeutical Medical Inc. (OTCQB: PRVCF) (CSE: PREV) (FSE: 18H) (PRVCF Profile) has developed an innovative cannabidiol (CBD)-based nose-to-brain delivery system for the relief of a number of medical conditions.

PreveCeutical Medical Inc. (PRVCF), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word "PreveCeutical" – a combination of the words "preventive" and "pharmaceutical" – was a precursor to the company's formation and incorporation in October 2015.

The company's first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical's research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical's gene-silencing technology would effectively "turn off" the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical's science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland's (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.'s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company's core. Disclaimer

PreveCeutical Medical Inc. Company Blog

PreveCeutical Medical Inc. News:

Fast-Growing Cannabis Industry Drives Biotech Research, Innovative Medical Therapy Development

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is “One to Watch”

PreveCeutical Announces Amendment to $3.28 Million Non-Brokered Private Placement

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.036, up 7.78%, on 8,096,080 volume with 419 trades. The stock’s average daily volume over the past 60 days is 13,915,343, and its 52-week low/high is $0.009/$0.16.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Global Payout, Inc. (GOHE), a client of NNW and a leading provider of comprehensive and customized prepaid payment solutions for domestic and international organizations distributing money worldwide. To view the full publication, titled “Blockchain to Streamline Cumbersome International Trade Transactions,” visit: https://www.networknewswire.com/blockchain-streamline-cumbersome-international-trade-transactions/

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

NetworkNewsWire Announces Publication on Blockchain Increasing Security and Efficiencies on an International Scale

MoneyTrac Technology, Inc. Executes LOI with Digital Signage Company, Eyeconic.TV, to Enhance Sales and Marketing of PotSaver

Global Payout Inc. Announces Launch of Official Audit in February 2018, Form 10-K to Follow in March

MGX Minerals Inc. (MGXMF)

The QualityStocks Daily Newsletter would like to spotlight MGX Minerals Inc. (MGXMF). Today, MGX Minerals Inc. closed trading at $1.4517, up 7.06%, on 233,843 volume with 209 trades. The stock’s average daily volume over the past 60 days is 247,408 and its 52-week low/high is $0.543/$2.119.

MGX Minerals Inc. (CSE:XMG) (FKT:1MG) (OTCQB:MGXMF) is pleased to report the Company is exercising its option to acquire an additional 5% ownership interest in engineering partner PurLucid Treatment Solutions (“PurLucid”) from existing shareholders in exchange for 1 million MGX shares. The Phase IV investment agreement share option exercise increases MGX’s ownership in PurLucid to 51%. The Company maintains the right to acquire 100% through successive future investments.

MGX Minerals Inc. (CSE: XMG) (FKT: 1MG) (OTCQB: MGXMF) is a diversified Canadian resource company developing large-scale mineral portfolios in specific commodities and jurisdictions in North America. The company controls significant interest in lithium, magnesium and silicon assets that offer streamlined development timelines and low capital expenditures. MGX Minerals and its engineering partner have developed a patent-pending, low-energy design process to extract valuable minerals from the abundant, highly mineralized brine wastewater produced each year by oil and gas companies.

This proprietary, petrolithium process rapidly concentrates lithium and other minerals from brine in less than a day. That's a stunning advancement from the conventional method of extracting minerals from brine through an evaporation process that can take up to 18 months, requires hundreds of acres of land, and averages less than a 50 percent mineral recovery rate. Using this advanced water purification technology, MGX Minerals cleans the wastewater that accompanies petroleum as it's being pulled up to the surface. The company's petrolithium process eliminates the need to inject contaminated wastewater back into the ground, which prevents drinking water contamination and possible earthquakes.

In January 2017, MGX Minerals successfully recovered concentrated lithium from heavy oil evaporator blowdown wastewater using its rapid recovery process, an accomplishment independently confirmed by the Saskatchewan Research Council. In August 2017, the company also successfully processed wastewater and lithium brine from eight North American projects at its one-cubic-meter-per-hour processing plant, proving the technology is economically viable. Research group Global Water Intelligence expects the wastewater treatment industry to grow into a $45 billion market annually by 2025, which suggests there are ample revenue-generating opportunities for MGX Minerals technology.

Lithium, the "white gold" of the new energy economy, is the key to clean energy development as global demand for hybrid and electric vehicles, high-drain portable electronic devices, and large-scale energy storage systems ramps up. Grand View Research, Inc. reports that the global lithium-ion battery market is expected to reach $93.1 billion by 2025. Current market forces show a high demand for lithium and a low supply, which further supports the necessity of MGX Mineral's cleaner, faster method of extracting high-value minerals from brine wastewater.

MGX Minerals is led by a team of industry standout performers who have worked in the mining and technology industries for decades. The leadership team is joined by an array of top-notch technical partners with unmatched experience in the oil and gas sectors, environmental services industry, marketing and product development, along with applied research and commercial development of technologies. Disclaimer

MGX Minerals Inc. Blog

MGX Minerals Inc. News:

MGX Minerals Increases Ownership Stake in Cleantech Engineering Partner PurLucid Treatment Solutions to 51%

MGX Minerals Announces 1.79% Li 186ppm Ta Over 6m at Case Lake Lithium, Ontario

MGX Minerals Strengthens Leadership Team to Execute California Lithium Strategy; Appoints Randall Keller as VP of Business Development

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $1.65, up 5.10%, on 325,881 volume with 420 trades. The stock’s average daily volume over the past 60 days is 515,966 and its 52-week low/high is $0.27/$2.54.

Lexaria Bioscience Corp. (OTCQX: LXRP) (CNSX: LXX) (the "Company" or "Lexaria") a drug delivery platform innovator, announces it has entered a definitive technology licensing agreement (the "Agreement") with Cannfections Group Inc. whereby Lexaria is providing its patented DehydraTECH™ technology to empower next-generation performance in cannabis infused chocolates and candies to be developed and sold in Canada and internationally. Also today, the company was featured by CannabisNewsWire in relation to a new report by the National Academies of Sciences, Engineering and Medicine is the most comprehensive analysis of existing research on e-cigarettes, according to the New York Times (http://cnw.fm/Eay21). This report highlights the importance of drug delivery methodologies like those developed by Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP).

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

Lexaria Enters Licensing Agreement with Canadian Cannabis Chocolate Manufacturer

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Technology Offers Potentially Safer Method of Delivering Drug Therapies

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Eyes Bright Future Following 2017 Success

Petroteq Energy Inc. (TSX.V:PQE) (OTCQX:PQEFF)

The QualityStocks Daily Newsletter would like to spotlight Petroteq Energy Inc. (PQEFF). Today, Petroteq Energy Inc. closed trading at $1.30, off by 5.80%, on 35,057 volume with 66 trades. The stock’s average daily volume over the past 60 days is 107,242, and its 52-week low/high is $0.015/$1.8892.

Petroteq Energy Inc. (TSXV: PQE; OTCQX: PQEFF; Frankfurt: A2DYWC), a company focused on the development and implementation of proprietary technologies for the energy industry, today announced an agreement with Pemex, the Mexican state-owned petroleum company and one of the world’s top petroleum producers. Also today, NetworkNewsWire issued a report on Petroteq Energy, Inc. (TSX.V: PQE) (OTCQX: PQEFF) (PQEFF Profile) discussing the value of blockchain-based PetroBloq (http://nnw.fm/b0thV) for global supply chain management.

Petroteq Energy Inc. (TSX.V: PQE) (OTCQB: PQEFF), with headquarters in Canada, seeks to create the world's largest pure-play cobalt exploration and development company. The company's current focus is on its Greater Cobalt Project located in Silver Centre, Ontario. The company is also in the midst of a three-way merger with Cobalt One Ltd. and CobalTech Mining Inc. and on completion First Cobalt will control over 10,000 hectares of prospective land and 50 historic mining operations in the Cobalt Camp in Ontario, Canada, as well as a mill and a permitted refinery facility.

The merger agreements with Cobalt One Ltd. and CobalTech Mining Inc., announced earlier this year, will result in a combined land position of more than 10,000 hectares (nearly 25,000 acres) in the Cobalt Camp containing approximately 50 past cobalt/silver producers and working mines. Initial test results from a mineralogical assessment of sample material taken from various historical mines located throughout the Cobalt Camp show both cobalt-rich and silver-rich mineralization styles. Samples taken at the former Bellellen mine, located within the Greater Cobalt Project in Ontario, show high grade cobalt assays, prompting First Cobalt to increase its drilling program at that site.

Petroteq Energy Inc. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world's current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

The company's clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, Petroteq Energy Inc. and its mining interests are primed for success.

Petroteq Energy Inc. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance. Disclaimer

Petroteq Energy Inc. Company Blog

Petroteq Energy Inc. News:

Petroteq Energy Announces Pemex as First Member of Petrobloq Global Blockchain Industry Consortium

Blockchain Yields Strong Potential in Global Supply Chain Management

Expectations for 2018 on Blockchain Applications in the Energy Industry


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(MOJO) +316.67%


Trader Power News
(LTBR) +58.60%


MarketClub Analysis
(MNKD) +41.26%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251